Journal of Clinical Virology
Volume 45, Issue 2 , Pages 114-118 , June 2009

Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression

  • Chau-Ting Yeh

      Affiliations

    • Liver Research Unit, Chang Gung Memorial Hospital, Taipei, Taiwan
    • Liver Cancer Research Center, Chang Gung University, Taoyuan, Taiwan
    • Corresponding Author InformationCorresponding author at: Liver Research Unit, Chang Gung Medical Center, 199, Tung Hwa North Road, Taipei, Taiwan. Tel.: +886 3 3281200x8102; fax: +886 3 3282824.
    • ,
  • Chao-Wei Hsu

      Affiliations

    • Liver Research Unit, Chang Gung Memorial Hospital, Taipei, Taiwan
    • ,
  • Yi-Cheng Chen

      Affiliations

    • Liver Research Unit, Chang Gung Memorial Hospital, Taipei, Taiwan
    • ,
  • Yun-Fan Liaw

      Affiliations

    • Liver Research Unit, Chang Gung Memorial Hospital, Taipei, Taiwan

Received 8 November 2008 ,Revised 11 February 2009 ,Accepted 20 April 2009.

References 

  1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107
  2. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 1988;8:493–496
  3. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut. 1991;32:294–298
  4. Liaw YF, Lin DY, Chen TI, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver. 1989;9:235–241
  5. Beasley RP. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer. 1988;61:1942–1956
  6. Chang CN, Skalski V, Zhou JH, Cheng YC. Biochemical pharmacology of (+)- and (−)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem. 1992;267:22414–22420
  7. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA. 1991;88:8495–8499
  8. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61–68
  9. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995;333:1657–1661
  10. Chien RN, Liaw YF. Short-term lamivudine therapy in patients with chronic hepatitis B. Intervirology. 2003;46:362–366
  11. Mason WS, Cullen J, Moraleda G, Saputelli J, Aldrich CE, Miller DS, et al. Lamivudine therapy of WHV-infected woodchucks. Virology. 1998;245:18–32
  12. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol. 1997;71:9392–9399
  13. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000;119:172–180
  14. Liaw YF. Therapy of chronic hepatitis B: current challenges and opportunities. J Viral Hepat. 2002;9:393–399
  15. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 1996;24:714–717
  16. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology. 1999;30:567–572
  17. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology. 2000;31:1318–1326
  18. Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther. 2004;9:679–693
  19. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology. 1998;27:628–633
  20. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest. 2001;107:449–455
  21. Torresi J, Earnest-Silveira L, Civitico G, Walters TE, Lewin SR, Fyfe J, et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the “fingers” subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology. 2002;299:88–99
  22. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology. 2003;38:1267–1273
  23. Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat. 2004;11:432–438
  24. Myers RP, Swain MG, Urbanski SJ, Lee SS. Reactivation of hepatitis B e antigen-negative chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal. Can J Gastroenterol. 2001;15:599–603
  25. Yeh CT, Lin WP, Hsu CW, Chang ML, Lin SM, Sheen IS. Emergence and takeover of precore-stop mutant prior to exacerbation of e antigen-negative chronic hepatitis B after withdrawal of lamivudine therapy. J Med Virol. 2006;78:906–910
  26. ACT-HBV Asia-Pacific Steering Committee Members. Chronic hepatitis B: treatment alert. Liver Int 2006;26:47–58.
  27. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. 2005;25:472–489
  28. Dusheiko G, Antonakopoulos N. Current treatment of hepatitis B. Gut. 2008;57:105
  29. Olivero OA, Beland FA, Fullerton NF, Poirier MC. Vaginal epithelial DNA damage and expression of preneoplastic markers in mice during chronic dosing with tumorigenic levels of 3′-azido-2′,3′-dideoxythymidine. Cancer Res. 1994;54:6235–6242
  30. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med. 1991;324:1699–1704
  31. Liu CJ, Chen BF, Chen PJ, Lai MY, Huang WL, Kao JH, et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis. 2006;193:1258–1265

PII: S1386-6532(09)00165-6

doi: 10.1016/j.jcv.2009.04.006

Journal of Clinical Virology
Volume 45, Issue 2 , Pages 114-118 , June 2009

Article Tools

* Image Usage & Resolution